Toll-like Receptor 4 Polymorphisms (rs4986790, rs4986791) and Serum Tumor Necrosis Factor Alpha levels in Chronic Obstructive Pulmonary Disease and Lung Cancer | ||
| SVU-International Journal of Medical Sciences | ||
| Article 9, Volume 8, Issue 1, January 2025, Pages 93-103 PDF (438.19 K) | ||
| Document Type: Original research articles | ||
| DOI: 10.21608/svuijm.2024.309849.1958 | ||
| Authors | ||
| Mostafa I. El-Amir1; Eman Abdelhamed* 1; Hagagy M. Mohammed2; Mohammed M. Wahman3; Mohamed Ali El-Feky4 | ||
| 1Department of Medical Microbiology and Immunology, Faculty of Medicine, South Valley University, Qena, Egypt. | ||
| 2Department of Chest Diseases and Tuberculosis, Faculty of Medicine, South Valley University, Qena, Egypt. | ||
| 3Department of Oncology and Nuclear Medicine, Faculty of Medicine, South Valley University, Qena, Egypt. | ||
| 4Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt. | ||
| Abstract | ||
| Background: Genetic factors and environmental conditions have a great impact on Chronic Obstructive Pulmonary Disease (COPD) and lung cancer (LC). Toll Like Receptor 4 (TLR4) gene polymorphisms may induce airway inflammation and cancer. Elevated TNF-α serum levels in COPD and LC patients exacerbate inflammation and disease progression. Objectives: To investigate the prevalence and type of TLR4 polymorphisms and TNF-α serum levels in COPD and LC susceptibility. Patients and methods: Case-control study with 50 COPD, 50 LC, and 50 healthy controls aged 19–75. DNA was extracted from blood samples, and PCR-RFLP and ELISA were used to evaluate TLR4 polymorphisms (rs4986790, rs4986791) and serum TNF-alpha. Results: Most LC patients (86%) were male compared to COPD (58%), P = 0.008. Smokers were 68% and 22% in LC and COPD patients, respectively, compared to 32% in controls (P < 0.001). Significantly, 38% of COPD patients were exposed to avian excreta compared to 0% of controls (P < 0.001). Genotyping of 896 A/G (SNP rs4986790) showed that 2% of LC patients were heterozygote with insignificance (P = 0.315) compared to control and COPD, and 4% were heterozygotes (CT) for 1196 C/T (SNP rs4986791) with insignificant (P = 0.153). Conclusion: The genotype (AA) of TLR4 (896 A/G) represents 98% and the genotype (CC) of TLR4 (1196 C/T) represented 96% of lung cancer cases. In COPD, both the genotype (AA) of TLR4 (896 A/G) and (CC) of TLR4 (1196 C/T) represented 100%. TNF-α had a significant negative correlation with chemotherapy. | ||
| Keywords | ||
| Toll-like receptor 4; TNF-α; COPD; Lung cancer | ||
|
Statistics Article View: 230 PDF Download: 125 |
||
